Apimeds Pharmaceuticals (APUS) welcomed the FDA’s newly released draft guidance on the development of non-opioid pain therapies, highlighting its potential to accelerate the company’s lead program, ...

"We cannot allow China and other countries to conquer this market," stated Von der Leyen, President of the Commission, in the ...